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Abstract
Background: Human T-lymphotropic virus type-1 (HTLV-1) is a deltaretrovirus that causes adult T-cell
leukemia/lymphoma and is implicated in a variety of lymphocyte-mediated disorders. HTLV-1 contains
both regulatory and accessory genes in four pX open reading frames. pX ORF-II encodes two proteins,
p13II and p30II, which are incompletely defined in the virus life cycle or HTLV-1 pathogenesis. Proviral
clones of the virus with pX ORF-II mutations diminish the ability of the virus to maintain viral loads in vivo.
Exogenous expression of p30II differentially modulates CREB and Tax-responsive element-mediated
transcription through its interaction with CREB-binding protein/p300 and represses tax/rex RNA nuclear
export.
Results: Herein, we further characterized the role of p30II in regulation of cellular gene expression, using
stable p30II expression system employing lentiviral vectors to test cellular gene expression with Affymetrix
U133A arrays, representing ~33,000 human genes. Reporter assays in Jurkat T cells and RT-PCR in Jurkat
and primary CD4+ T-lymphocytes were used to confirm selected gene expression patterns. Our data
reveals alterations of interrelated pathways of cell proliferation, T-cell signaling, apoptosis and cell cycle in
p30II expressing Jurkat T cells. In all categories, p30II appeared to be an overall repressor of cellular gene
expression, while selectively increasing the expression of certain key regulatory genes.
Conclusions: We are the first to demonstrate that p30II, while repressing the expression of many genes,
selectively activates key gene pathways involved in T-cell signaling/activation. Collectively, our data
suggests that this complex retrovirus, associated with lymphoproliferative diseases, relies upon accessory
gene products to modify cellular environment to promote clonal expansion of the virus genome and thus
maintain proviral loads in vivo.
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Background
Human T-lymphotropic virus type 1 (HTLV-1), the first
characterized human retrovirus, causes adult T cell leuke-
mia/lymphoma (ATL) and is associated with several lym-
phocyte-mediated disorders such as HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) [1].
Mature CD4+ T lymphocytes are the primary targets of
HTLV-1 infection [2]. Although the mechanism by which
the virus causes oncogenic transformation of host T lym-
phocytes is incompletely understood, altered gene expres-
sion has been associated with the initiation or progression
of ATL [3]. This complex retrovirus encodes structural and
enzymatic gene products, as well as regulatory and acces-
sory proteins from open reading frames (ORF) in the pX
region between env and the 3' long terminal repeat (LTR)
of the provirus [4]. The well characterized Rex and Tax
proteins are encoded in the ORF III and IV respectively.
Rex is a nucleolus-localizing phosphoprotein, involved in
nuclear export of unspliced or singly spliced viral RNA [5].
Tax is a nuclear and cytoplasmic localizing phosphopro-
tein that interacts with cellular transcription factors and
activates transcription from the viral promoter, Tax-
responsive element (TRE) and enhancer elements of vari-
ous cellular genes associated with host cell proliferation
[6]. Emerging evidence has documented the role of pX
ORF I and II gene products in the replication of HTLV-1
[7,8]. There are four proteins expressed from these ORFs –
p12I, p27I, p13II, and p30II. pX ORFs I and II mRNAs are
present in infected cell lines and freshly isolated cells from
HTLV-1-infected subjects [9], as well as in ATL and HAM/
TSP patients [10]. Antibodies [11,12] and cytotoxic T cells
[13] that recognize recombinant proteins or peptides of
the pX ORF I and II proteins are present in HTLV-1
infected patients and asymptomatic carriers.
Using molecular clones of HTLV-1 with selective muta-
tions of ORF I and II, we have tested the requirement of
p12I and p13II/p30II in the establishment of infection and
maintenance of viral loads in a rabbit model of infection
[14-16]. ORF II protein p30II contains a highly conserved
bipartite nuclear localization signal (NLS) and localizes
within the nucleus of cells [17-19]. In addition, p30II con-
tains serine- and threonine-rich regions with distant
homology to transcription factors Oct-1 and -2, Pit-1, and
POU-M1 [20]. Previous studies from our laboratory have
demonstrated that p30II also co-localizes with p300 in the
nucleus and physically interacts with CREB binding pro-
tein (CBP)/p300 and differentially modulates cAMP
responsive element (CRE) and TRE mediated transcrip-
tion [18,21]. Recent reports also indicate a post-transcrip-
tional role of HTLV-1 p30II  and HTLV-2 p28II
(homologous protein encoded in the HTLV-2 pX ORF II
region), in modulating the export of tax/rex RNA from the
nucleus [22,23]. Therefore, p30II appears to be a multi-
functional protein with transcriptional and post-tran-
scriptional roles in regulating viral gene expression. Based
on these reports, we hypothesized that p30II functions as
a regulator of cellular and viral gene expression to pro-
mote HTLV-1 replication.
Gene arrays have primarily been employed to study the
changes in gene expression profile of HTLV-1-immortal-
ized and transformed cell lines or in cells from ATL
patients and attempts to test the influence of individual
HTLV-1 viral proteins on cellular gene expression have
been limited to Tax [3,24-27]. Herein we used the Affyme-
trix U133A human gene chip to confirm the role of p30II
as a regulator of gene expression and identified several
novel and important alterations in gene expression pro-
files, unique to cell cycle regulation, apoptosis and T cell
signaling/activation. In addition, using semi-quantitative
RT-PCR, we have confirmed the expression of multiple
genes modulated by p30II in Jurkat T cells and primary
CD4+ T lymphocytes. We then tested the influence of
p30II in T cell signaling using reporter assays representing
critical T lymphocyte transcription factors. This is the first
report that demonstrates the role of p30II as an activator of
key transcription factors involved in T cell signaling/acti-
vation. Together, our data suggests that HTLV-1, a com-
plex retrovirus associated with lymphoproliferative
disorders, uses accessory genes to promote lymphocyte
activation to enhance clonal expansion of infected cells
and maintain proviral loads in vivo.
Results
p30II and Analysis of Cellular Gene Expression in Jurkat T 
Lymphocytes
Stable expression of HTLV-1 p30II in Jurkat T lymphocytes
was established using recombinant lentiviruses (Fig. 1). At
10 days post-transduction, GFP expression was greater
than 95% in Jurkat T lymphocytes transduced with recom-
binant lentivirus expressing GFP alone (controls) or p30II
and GFP (samples) (Fig. 2). RT-PCR was used to confirm
the expression of p30II mRNA in the sample cells and
absence of p30II mRNA expression in control cells (Fig. 2).
p30II protein expression was also confirmed by western
immunoblot assay (data not shown) using methods as
previously reported [28]. Differential gene expression and
comparative analysis was done to identify probes with at
least 1.5 fold difference in expression between control and
p30II and verified for cluster formation [29]. Quality con-
trol criteria evaluations included comparison of the ratios
of 3' signal to 5' signal of two housekeeping genes, beta-
actin and GAPDH, which were between 0 and 3. Addi-
tional hybridization controls were used in each array and
included BioB, BioC, BioD, and Cre. These controls were
all present and in a linear relationship of intensity. Quan-
titative RNA levels were determined by comparing the
average differences representing the perfectly matched
minus the mismatched for each gene-specific probe setRetrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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before analysis with data mining software to identify
probes with at least 1.5 fold differences [29,30].
We then categorized genes deregulated by HTLV-1 p30II
into those upregulated or downregulated in expression.
We further grouped genes deregulated by p30II based on
their functions, such as apoptosis, cell cycle, cell adhesion,
transcription/translation factors and T cell activation or
cell signaling. In all the categories, p30II was an overall
repressor of cellular gene expression, while selectively
increasing the expression of certain key regulatory genes
(Table 1, see Additional file 1). The total number of genes
of known biological or molecular function that were
decreased in expression was 318 compared to 126 genes
that were increased in expression.
p30II Modulates Multiple Cellular Gene Networks
Based on changes in gene expression in p30II expressing
cells (Table 1), p30II would be predicted to modulate
apoptosis. These include Bcl-2 related/interacting genes
such as anti-apoptotic Bcl-2-related protein A1, anti-apop-
totic MCL1, cell-death regulator Harakiri, apoptotic pro-
tector BNIP1 (downregulated) and pro-apoptotic BIK
(upregulated). In addition, p30II  expression correlated
with downregulation of genes associated with Fas medi-
ated apoptosis pathway such as tumor suppressing
subtransferable candidate 3 and TNF receptor superfamily
member 25. p30II expression was also associated with
decreased expression of caspases (2 and 4) and increased
expression of genes associated with the DNA fragmenta-
tion pathway (CIDE-B and CIDE-3). In addition, p30II
expression correlated with decreased expression of many
other apoptosis related genes including CD28, Lck, cyclin
B1, Cullin 5, Adenosine A2a receptor, TAF4B and NCK-
associated protein 1.
Multiple genes involved in cell cycle regulation were
altered in p30II expressing Jurkat T lymphocytes. These
include checkpoint suppressor 1, cytosolic branched-
chain amino acid transaminase 1, histone deacetylase 6,
cyclin B1, WEE1 kinase, CDC14A, Lck, JAK2, GAS7,
BZAP45, Cullin, Rab6 GTPase activating protein (down-
regulated) and TERF1, AKAP8, DDX11, MSH2 and JUN-D
(upregulated). Another gene down regulated by p30II
expression was MDM2, which is over expressed in certain
types of leukemia [31] and capable of enhancing the tum-
origenic potential of cells by inhibiting p300/PCAF medi-
ated p53 acetylation [32].
p30II expression was associated with altered expression of
several genes involved in cell-to-cell adhesion. These
include decrease in integrin (integrin β8) immunoglobu-
lin (MADCAM1), a counter-receptor for P-selectin
(SELPLG), cadherin (desmocollin 3), protocadherin (PC-
LKC) liprin (PPF1BP1), CD84/Ly-9, CD58, CD43/sialo-
phorin and glycosyl-phosphatidyl-inositol phospholipase
D1. Expression of p30II  correlated with increase in
integrin receptor α1 subunit and KIT ligand.
A number of genes encoding transcriptional control fac-
tors or regulators of transcription were repressed in p30II
expressing Jurkat T lymphocytes. These included
decreased expression of TATA-binding protein associated
factor 4 (TAF4), two co-repressors (Enolase-1 and Chro-
mosome 19 ORF2 protein), a novel specific coactivator
for mammalian TEFs, namely TONDU [33], homeo box
genes (mesenchyme homeo box 1, homeobox A1), T-box
genes (T-box 21) and proteins containing helix-loop-helix
domain, which are known to be critical in cell growth/dif-
ferentiation and tumorigenesis (neuronal PAS domain
protein 2, Myc-associated factor protein, inhibitor of DNA
binding-3). Additionally, p30II expression correlated with
down regulation of zinc finger proteins (zinc finger pro-
tein 36), a group of transcription regulators proposed to
be candidates in malignant disorders [34] and coiled coil
proteins (JEM-1). p30II was also associated with downreg-
ulation of many genes with positive transcriptional effects
(including SEC14-like 2, Nurr 1, CITED2/MRG1, LXR
alpha and SMARCA2). Reduced expression of HDAC6, a
histone deacetylase and nuclear receptor coactivator 3
(CBP interacting protein) with histone acetyltransferase
Schematic illustration of lentiviral vectors expressing both  p30HA and GFP (sample vector) as bicistronic messages and  GFP alone (control vector) from elongation factor 1 alpha  promoter Figure 1
Schematic illustration of lentiviral vectors expressing 
both p30HA and GFP (sample vector) as bicistronic 
messages and GFP alone (control vector) from elon-
gation factor 1 alpha promoter. Abbreviations: LTR – 
Long Terminal Repeats; RRE – Rev Response Element; EF1 α 
– Elongation Factor 1 alpha promoter; IRES – Internal Ribos-
ome Entry Site; WPRE – Woodchuck Hepatitis Post-tran-
scriptional Regulatory Element.
p30
II-HA Lentiviral Vector
5’ LTR  RRE EF1α α α α p30
II IRES GFPRetrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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Triplicate p30II samples express GFP and p30II while triplicate controls express only GFP Figure 2
Triplicate p30II samples express GFP and p30II while triplicate controls express only GFP. (A) Flow cytometric 
analysis illustrating the expression of GFP in Jurkat T cells 10 days post spin-infection with lentiviral vectors. Both sample 
(expressing p30II and GFP) and control (GFP alone) group contains relatively high and similar levels of GFP. (B) RT-PCR dem-
onstrating the expression of p30II in Jurkat T cells 10 days post spin-infection with lentiviral vectors. Jurkat T cells spin-infected 
with sample vector express p30II while the control vector spin-infected cells do not express p30II. RT-PCR was performed with 
triplicate samples and controls. GAPDH was used as a control for the integrity of the message. (C) Representative western 
blot showing p30II expression from cell lysate (p30II migrates at ~28 kD). M = Mock vector infected cell lysate, p30 lv = p30 len-
tivirus vector infected cell lystate, MW = biotin molecular weight markers.
- 30 KD 
- 20 KD 
p30
II
Mock           p30 lv        MW 
A.
B. 
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and pCAF/CBP recruiting abilities [35] are particularly
interesting, since p30II contains multiple highly conserved
lysines, which could play a role in acetylation [18,21].
Expression of p30II was also associated with decrease in
GAS 7, which has sequence homology to Oct and POU
family of transcription factors [36] and decreased expres-
sion of translation initiation factor 2 (IF2) and eukaryotic
translation elongation factor 1δ (EEF1D). In contrast,
p30II expression in Jurkat T lymphocytes was associated
with an increase in expression of eukaryotic translation
elongation factor 1α (EEF1A2), a putative oncogene [37],
and enhanced expression of HTLV enhancer factor, Jun-D,
TAF1C, Kruppel-type zinc finger, PQBP1, AF4 and SOX4.
p30II Expression Alters Patterns of T-Cell Signaling Gene 
Networks
Genes involved in T-cell signaling were differentially
affected by p30II expression. Expression of p30II was asso-
ciated with decreased expression of CD28, a co-stimula-
tory molecule with a distinct role in T lymphocyte
activation [38] and reduced gene expression of CD46 and
Lck tyrosine kinase, a member of the Src family of tyrosine
kinases activated by T cell surface receptors [39]. In con-
trast, cells expressing p30II had enhanced Vav-2 and CD72
gene expression. Additionally, p30II expression correlated
with decrease in the level of CHP, an endogenous cal-
cineurin inhibitor, which would be predicted to promote
NFAT expression by p30II (see below). Moreover, p30II
expression was associated with increased expression of
Jun-D and c-Fos, suggesting activation of AP-1 mediated
transcription. p30II  expression was associated with
decreased expression of protein kinase D (PKD), which
negatively modulates JNK signaling pathway [40], medi-
ates cross-talk between different signaling systems, and is
critical in processes as diverse as cell proliferation and
apoptosis [41]. Interestingly, in Jurkat T lymphocytes
expressing p30II, there were no detectable levels of I kappa
B kinase gamma (IKKγ), which is important for NF-κB sig-
naling in response to both T cell activation signals and Tax
[42]. p30II  expression was associated with increased
Hematopoetic Progenitor Kinase-1 (HPK-1), a known NF-
κB activator [43]. p30II expression was also associated
with decreased Ras GRP2, a guanyl nucleotide exchange
factor that increases Ras-GTP, suggesting a decrease in the
level of activated Ras (Ras-GTP). Seminquantitative RT-
PCR analysis in Jurkat T lymphocytes and primary CD4+
T lymphocytes correlated directly with the gene array and
confirmed the altered expression of each of three selected
genes involved in these T cell activation/signaling path-
way (Fig. 3A through 3D).
p30II Influences NFAT, NF-κB and AP-1-mediated 
Transcription in Co-Stimulated Jurkat T lymphocytes
Using luciferase reporter assays, we directly tested the abil-
ity of p30II to influence NFAT, NF-κB and AP-1 driven
transcription, all key transcription factors in T cell activa-
tion. Although p30II  expression overall resulted in a
repressive pattern of gene expression, our data indicated
that the viral protein selectively alters the cellular environ-
ment to promote NFAT, NF-kB and AP-1 mediated tran-
scription in Jurkat T cells undergoing co-stimulation. We
transiently co-transfected NF-κB, AP-1, or NFAT luciferase
reporter plasmids and a p30II expression plasmid into Jur-
kat T lymphocytes, and then stimulated the cells with well
established co-stimulators of T cells including PMA or
ionomycin or both, anti-CD3 or anti-CD28 or both. p30II
increased the NFAT driven luciferase reporter gene activity
from 2.2 to 10.7 fold depending on co-stimulatory treat-
ment (Fig. 4A), indicating that p30II effectively enhanced
NFAT driven transcription, when stimulated with iono-
mycin or anti-CD3. NF-κB driven luciferase reporter gene
activity was increased from 3.1 to 11.4 fold, depending on
co-stimulation (Fig. 4B). However, p30II only modestly
increased AP-1-driven luciferase reporter gene activity
from 1.2 to 5.2 fold in the presence of co-stimulator treat-
ments (Fig. 4C). Collectively, these data indicate that
p30II selectively promotes NFAT, NF-kB and AP-1 medi-
ated transcription in Jurkat T lymphocytes undergoing co-
stimulation and thus would be predicted to favor cell sur-
vival or influence cell activation.
Discussion
Our study represents a comprehensive analysis of gene
expression patterns influenced by a retrovirus accessory
protein in T lymphocytes. Overall, this study confirmed
that p30II is a regulator of cellular genes, either directly or
indirectly, and also identified several potential new func-
tional roles for p30II. Our approach included methods to
strengthen the reliability of our data by (a) use of triplicate
samples and appropriate controls (b) use of multiple soft-
ware for data analysis (c) minimization of nonspecific
hybridization and background signals by using Affymetrix
chip [44] (d) use of a well-characterized T lymphocyte sys-
tem (Jurkat) and (e) verification of microarray data by
semiquantitative RT-PCR in Jurkat T lymphocytes and pri-
mary CD4+ T lymphocytes (f) validation of microarray
data by reporter assays, all of which were consistent with
our micro array findings. Some of these findings are con-
sistent with previous studies using gene arrays to test
HTLV-1-transformed cell lines. For example, HTLV-1
infected cell lines contain low levels of caspase-4 and high
levels of JUN [3] and cyclin B1 levels are low in HTLV-1
leukemic T cells [45]. Our study represents a
comprehensive analysis of gene expression patterns influ-
enced by a retrovirus accessory protein in T lymphocytes.
An important caveat our approach of using gene arrays is
that this method, while useful to indicate if an individual
gene is increased or decreased in expression and therefore
predicted to influence a cell signaling pathway, does not
reveal the composite of transcription regulation in vivo.Retrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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This may explain, in part, why our reporter gene data,
which is more dependent upon the availability of tran-
scription factors in total, may not directly, correlate to an
individual gene expression result.
Others have used gene array approaches to study HTLV-1-
related changes in gene expression. Harhaj et al [24] stud-
ied the gene expression in HTLV-1 mediated oncogenesis
using human cDNA array analysis of normal and HTLV-1
immortalized T cells and found that the expression of a
large number of genes involved in apoptosis were deregu-
lated in HTLV-1 immortalized T cells. Subsequently, the
same type of cDNA arrays were employed by De La Fuente
et al [25] to study upregulation of a number of transcrip-
tion factors in HTLV-1-infected cells, including zinc fin-
gers, paired domains, and basic helix-loop-helix (bHLH)
proteins. Gene expression profiles of fresh peripheral
blood mononuclear cells (PBMC) from acute and chronic
ATL patients were used to identify the genes associated
with progression of ATL including a T cell differentiated
antigen (MAL), a lymphoid specific member of the G-pro-
tein-coupled receptor family (EBI-1/CCR7) and a novel
Semiquantitative RT-PCR of CHP, JUN-D and NFATc in controls and p30II expressing Jurkat T lymphocytes (A and B) and pri- mary CD4+ T lymphocyte (C and D) samples Figure 3
Semiquantitative RT-PCR of CHP, JUN-D and NFATc in controls and p30II expressing Jurkat T lymphocytes 
(A and B) and primary CD4+ T lymphocyte (C and D) samples. PCR products were separated by electrophoresis (A 
and C), normalized to GAPDH and quantified by densitometry (B and D). In panel B, dark grey bars indicate indicate p30II 
expressing cells and light grey bars indicate control (empty vector) cells. In panel D, dark grey bars indicate indicate p30II 
expressing cells and white bars indicate control (empty vector) cells. Data points are mean of triplicates. CHP was downregu-
lated while JUN-D and NFATc was upregulated by p30II. Fold decrease/increase in activity in the presence of p30II are indicated 
above each bar.Retrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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human homolog to a subunit (MNLL) of the bovine ubi-
quinone oxidoreductase complex [26]. Using NIH Onco-
Chip cDNA arrays containing 2304 cancer related cDNA
elements, Ng et al, 2001 [27] compared normal and Tax-
expressing Jurkat T lymphocytes and identified Tax
induced changes in gene expression, associated with
apoptosis, cell cycle, DNA repair, signaling factors,
immune modulators, cytokines, growth factors, and adhe-
sion molecules. Recently, Affymetrix, GeneChip
microarrays containing oligonucleotide hybridization
probes representative of ~7000 genes were used to com-
pare the expression profiles of normal activated periph-
eral blood lymphocytes to HTLV-I-immortalized and
transformed cell lines [3]. In this study, by employing a
gene chip representing ~33000 genes, we tested the role of
p30II  on cellular gene expression profile of a larger
number of genes. Gene expression data from cells in
which exogenously expressed proteins, which may also be
tagged for identification, may not represent what would
occur during the natural infection. However, these pat-
terns provide important clues for functional alterations
which may occur during the viral protein expression. The
"natural" or in vivo amount of expression of regulatory
and accessory gene products encoded from the HTLV-1 pX
gene region has not been clearly defined. Recent studies
using RT-PCR analysis of cell lines suggests that pX ORF 1
p30II activates NFAT, AP-1 and NF-κB transcriptional activity in Jurkat T lymphocytes Figure 4
p30II activates NFAT, AP-1 and NF-κB transcriptional activity in Jurkat T lymphocytes. Black bars indicate control 
and grey bars indicate p30II. Data points are mean of triplicate experiments. Fold increase in activity in the presence of p30II is 
indicated above each bar. p30II increased the NFAT-luc activity from 2.2 to 10.7 fold depending on co-stimulatory treatment 
e.g., PMA, ionomycin, CD3, CD28 etc. (A), p30II increased NF-κB-luc activity from 3.1 to 11.4 fold (B) and modestly increased 
the AP-1 driven luciferase reporter gene activity from 1 to 5 fold in the presence of co-stimulator treatments (C).Retrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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and 2 mRNA is expressed at significantly lower amounts
compared to tax/rex mRNA, full length genomic, or singly
spliced envelope mRNA [46].
Expression from the IL-2 promoter requires binding of
several transcription factors, including NFAT, AP-1 and
NF-κB. NFAT is vital to proliferation of peripheral lym-
phocytes for HTLV-1 infection [47] while AP-1 is linked to
the dysregulated phenotypes of HTLV-1 infected T cells
[48] and malignant transformation [49]. Activation of AP-
1 occurs through Tax-dependent and independent mech-
anisms in HTLV-1-infected T cells in vitro and in leukemia
cells in vivo [48]. NF-κB is highly activated in many hemat-
opoietic malignancies, HTLV-1 infected T cell lines and in
primary ATL cells, even when Tax expression levels are low
[49] and due to its anti-apoptotic activity, it is considered
to be a key survival factor for several types of cancer. Ours
is the first report demonstrating the ability of an HTLV-1
accessory protein to have broad modulating activities on
the transcriptional activity of NF-κB, NFAT and AP-1. Fur-
ther studies will be required to confirm the mechanisms
of p30II in T cell activation and to test the comparative role
of p30II expression in context to other regulators of tran-
scription such as Tax.
We have previously reported that another HTLV-1 acces-
sory protein p12I stimulates NFAT mediated transcription,
when stimulated with PMA, indicating that p12I acts syn-
ergistically with Ras/MAPK pathway to promote NFAT
activation and thus may facilitate host cell activation and
establishment of persistent HTLV-1 infection [50]. Our
data indicates that p30II enhanced NFAT driven transcrip-
tion significantly when stimulated with ionomycin or
CD3, and therefore likely uses a different mechanism than
p12I. To modulate NFAT driven transcription and subse-
quent T cell activation/signaling, it is possible that these
two accessory proteins act synergistically. AP-1 is able to
interact with transcriptional coactivator CBP/p300, as
well as viral CREs and mediate HTLV-1 gene expression
[48,51,52]. Intriguingly, we have previously reported that
p30II interacts with CBP/p300 at the KIX domain of CBP,
influences CRE and TRE mediated transcription [18] and
disrupts CREB-Tax-p300 complexes on TRE probes [21].
NF-κB and NFAT [53] are also known to interact with the
transcriptional coactivator CBP/p300. Therefore, it is pos-
sible that p30II  modestly activates the transcriptional
activity of NFAT, NF-κB and AP-1, at least in part, by its
interaction with CBP/p300. In parallel, the HIV-1 acces-
sory protein Vpr causes a modest increase in NF-κB, NFAT
and AP-1 mediated transcription in a cell-cycle dependent
fashion by causing G2 arrest [54]. Similar to HIV-1 Vpr,
our gene array findings indicate that HTLV-1 p30II expres-
sion was associated with decrease in cyclin B1 and WEE1
kinase levels, suggesting that p30II expression likely cause
G2 arrest and may thus modulate transcriptional activity
of NFAT, NF-κB and AP-1, in a cell-cycle dependent man-
ner. An important caveat of our data is the use of Jurkat T
cells, which while representing human T cells, are IL-2
independent and transformed. Thus, differences in
responsive genes expected from non-transformed T cells
for the transcription factors screened in our study may be
due to our cell line model.
HTLV-1 mediated interference with normal T-cell apopto-
sis is thought to be a mechanism of tumorigenicity [2],
but specific mechanisms by which HTLV-1 infection or
any particular HTLV-1 gene products influence on T-cell
survival are not fully understood. Similar to the effect of
HTLV-1 Tax on apoptosis related genes [24,27], we found
that p30II also deregulates multiple genes resulting in pos-
sible pro-apoptotic and anti-apoptotic effects. Since apop-
tosis is a well-known mechanism of cellular defense
against viral infection, a possible role of p30II in lym-
phocyte apoptosis might correlate with the requirement
of p30II in maintaining proviral loads in vivo [15]. Previ-
ous studies indicate that several members of the cell cycle
machinery have altered expression in HTLV-1 infected
cells [3]. Several recent studies have reviewed the aberra-
tions in cell cycle caused by HTLV-1 Tax [6,55].
p30II appears to regulate viral gene expression and modu-
late immune response. We have previously reported that,
p30II activated HTLV-1 LTR at lower concentrations and
repressed at higher concentrations [18]. Interestingly,
p30II expression was associated with downregulation of
lck (p56), which suppresses the HTLV-1 promoter [56]
and upregulate HTLV enhancer factor, which is known to
bind to LTR at a region involved in regulation of gene
expression by the ets family of transcription factors [57].
Additionally, p30II expression was associated with altered
expression of cellular genes involved in immune modula-
tion such as CD46, CD43, CD58, IFNγ and CD72.
Conclusions
Overall, this study supports our earlier reports on the
repressive role of HTLV-1 p30II  in gene expression
[18,21,23] and sheds light on potential mechanisms by
which p30II functions in HTLV-1 replication or leukemo-
genesis. Our data confirmed that p30II while a negative
regulator of cellular genes, also influences T cell signaling,
apoptosis and the cell cycle. Many of the effects of p30II
appear to overlap or counteract the influence of other
HTLV-1 regulatory proteins like Tax or other accessory
proteins such as p12I. It is possible that these proteins act
coordinately or synergistically. We postulate that, by mod-
ulating the expression of various HTLV-1 proteins, the
virus employs selective use of these viral proteins during
different stages of the infection. However, since informa-
tion on the expression profile of HTLV-1 proteins during
stages of the infection is limited, additional studies areRetrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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required to explore this possibility. Such future studies
might provide new directions in the development of ther-
apeutic interventions against HTLV-1 disorders, which are
associated with immune-mediated mechanisms.
Methods
Lentiviral vectors and other plasmids
The plasmid pWPT-IRES-GFP was generated by cloning
the internal ribosome entry site (IRES) sequence from
pHR'CMV/Tax1/eGFP [58] (Gerald Feuer, SUNY, Syra-
cuse) into pWPT-GFP plasmid (Didier Trono, University
of Geneva). Subsequently, the plasmid pWPT-p30IIHA-
IRES-GFP was created by cloning the p30II sequence from
ACH [59] with the downstream influenza hemagglutinin
(HA1) tag (Fig. 1). Sanger sequencing confirmed both the
plasmids to have the correct sequence and were in frame.
GFP and p30IIHA expression were confirmed by fluores-
cence activated cell sorting (FACS) analysis (Beckman
Coulter, Miami, FL) and western blot respectively. GFP
expression from each of the plasmids was confirmed by
flow cytometry (Beckman Coulter) and the p30IIHA
expression from pWPT-p30IIHA-IRES-GFP plasmid was
confirmed by western blot using mouse monoclonal anti-
hemagglutinin antibody (1:1000) (Covance, Princeton,
NJ) as described previously [18,21]. The plasmid pME-
p30IIHA was created by cloning p30II sequence from ACH
with HA1 tag, into pME-18S (G. Franchini, NIH). Other
plasmids used include previously reported pRSV-βGal
[18] and AP-1, NF-κB and NFAT-luciferase reporter plas-
mids [50].
Recombinant lentivirus production and infection of Jurkat 
T lymphocytes and primary CD4+ T lymphocytes
Recombinant lentiviruses were produced by transfecting
pHCMV-G, pCMV∆R8.2 and pWPT-p30IIHA-IRES-GFP
(sample) or pWPT-IRES-GFP (control) as described previ-
ously [60]. Briefly, 293T cells (5 × 106) were seeded in a
10-cm dish and transfected the following day with 2 µg of
pHCMV-G, 10 µg of pCMV∆R8.2 and 10 µg of pWPT-
p30IIHA-IRES-GFP or pWPT-IRES-GFP using the calcium
phosphate method. Supernatant from 10 to 20 dishes was
collected at 24, 48 and 72 h post transfection, cleared of
cellular debris by centrifugation at 1000 rpm for 10 min
at room temperature and then filtered through a 0.2 µm
filter. The resulting supernatant was then centrifuged at
6,500 g for 16 h at 4°C. The viral pellet was suspended in
cDMEM (DMEM containing 10% FBS and 10% strepto-
mycin and penicillin) overnight at 4°C and the concen-
trated virus was aliquoted and stored at -80°C. To
determine the virus titer, serial dilutions of the virus stock
were used to spin infect 293T cells and 48 h post infection,
eGFP expression and p30II expression was measured by
flow cytometry and RT-PCT respectively. Briefly, on the
day before infection, 293T cells (1 × 105) were seeded in a
6-well plate. The medium was removed the following day
and the cells were then incubated with the diluted virus
containing 8 µg/ml polybrene (Sigma, St. Louis, MO).
Cells were then spin-infected by centrifugation at 2700
rpm for 1 h at 30°C, supplied with fresh medium and cul-
tured for 48 h. Then cells were treated with trypsin
(Invitrogen, Carlsbad, CA), pelleted and resuspended in
D-PBS (Invitrogen) for fluorescence activity cell sorting
(FACS) analysis on an ELITE ESP flow cytometer (Beck-
man Coulter). One × 106 cells were used to perform west-
ern blot to detect the expression of p30II HA. Jurkat T
lymphocytes (clone E6.1, American Type Culture Collec-
tion) were transduced with recombinant virus at multi-
plicity of infection of 4 in the presence of 8 µg/ml
polybrene (Sigma) and spin-infected at 2700 rpm for 1 h
at 25°C. Primary CD4+ T cells were extracted using dyna-
bead CD4 positive isolation kit (Dynal Biotech, Lake Suc-
cess, NY) according to manufacturer's instructions.
Primary CD4+ T cells were stimulated with Phytohemag-
glutinin (PHA) for 48 h, transduced with recombinant
virus at multiplicity of infection of 20 in the presence of 8
µg/ml polybrene (Sigma) and spin-infected at 2700 rpm
for 1 h at 25°C. At 10 days post-transduction, GFP expres-
sion of controls and samples were verified to be above
90% by FACS analysis and the presence of p30II mRNA
expression in samples (and absence in controls) was veri-
fied by RT-PCR (Fig. 2).
Western Immunoblot assay
Cells were lysed in buffer containing phosphate-buffered
saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
0.1% sodium dodecyl sulfate (SDS). Cell lysates were pre-
pared by centrifugation at 14,000 rpm (Beckman) for 20
min at 4°C. Protein concentrations were determined by
BCA assay (micro-BCA Protein Assay®, Pierce, IL). Equal
amounts of proteins were mixed with Laemmli buffer
(62.5 mM Tris [pH 6.8], 2% SDS, 10% glycerol, 0.2%
bromophenol blue, 100 mM dithiothreitol). After boiling
for 5 min, samples were electrophoresed through 12%
polyacrylamide gels. The fractionated proteins were trans-
ferred to nitrocellulose membranes (Amersham Pharma-
cia Biotechnology) at 100 V for 1 h at 4°C. Membranes
were blocked with 5% non-fat dry milk in PBS with 0.1%
Tween for 16 hours, then incubated with mouse anti-HA
monoclonal Ab (1:1,000) (clone 16B-12) (Covance
Research Products, Princeton, NJ), for overnight at 4°C,
and developed by using horseradish peroxidase-labeled
secondary Ab (1:1,000) and enhanced chemilumines-
cence reagent (Cell Signaling Technology, Beverly, MA).
Probe preparation and microarray analysis
According to the instructions of manufacturers, total cel-
lular RNA was isolated from transduced Jurkat T lym-
phocytes using RNAqueous (Ambion, Austin, TX). To test
the concentration and purity of the RNA samples, absorb-
ance at 260 nm and 280 nm were measured and the 260/Retrovirology 2004, 1:39 http://www.retrovirology.com/content/1/1/39
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280 ratio was calculated using a spectrophotometer
(Genequant, Amersham Pharmacia, Piscataway, NJ). The
260/280 ratio of all the RNA samples were between the
range of 1.9–2.1. The probe preparation for GeneChip
was performed according to the Affymetrix GeneChip
Expression Analysis Technical Manual (Affymetrix, Santa
Clara, CA). Briefly, cDNA was synthesized using genechip
T7-Oligo (dT) promoter primer kit (Affymetrix) and
superscript double stranded cDNA synthesis kit (Invitro-
gen), according to the manufacturers instructions. cDNA
cleanup was done using Genechip Sample Cleanup mod-
ule (Affymetrix). In vitro transcription was performed on
the cDNA to produce biotin-labeled cRNA with ENZO
RNA Transcript labeling kit (Affymetrix), according to the
manufacturer's instructions. Complimentary RNA (cRNA)
cleanup was performed using Genechip Sample Cleanup
module (Affymetrix). The quality of total RNA and biotin-
labeled cRNA of all the samples and controls were
checked by calculating the ratio of absorbance at 260 nm
and 280 nm (between 1.9 to 2.1) using a spectrophotom-
eter (Genequant) and agarose gel electrophoresis. The
labeled cRNA was fragmented to 50–200 nucleotides, and
hybridized to U133A arrays (Affymetrix) using GeneChip®
Hybridization Oven (Affymetrix). Arrays were washed
and stained using GeneChip®  Fluidics Station 400
(Affymetrix) and scanned by GeneArray Scanner
(Affymetrix).
Quality control criteria evaluations done as part of the
basic analysis include (1) The ratios of 3' signal to 5' signal
of two housekeeping genes, beta-actin and GAPDH were
between 0 and 3. (2) The hybridization controls BioB,
BioC, BioD, and Cre were all present and in a linear rela-
tionship of intensity. (3) The scale factors between arrays
did not vary by 3 fold. (4) The background intensity was
not significantly higher than expected. (5) The percent of
gene present was monitored and found to be not less than
the standard 30%. To determine the quantitative RNA
level, the average differences representing the perfectly
matched minus the mismatched for each gene-specific
probe set was calculated. Differential gene expression and
comparative analysis was done using Data Mining Tool®
(Microarray suite 5) to identify probes with at least 1.5
fold difference in expression between control and p30II
and verified for cluster formation by dCHIP software [29].
The biological and molecular functional grouping of these
probes was done using Gene Ontology Mining Tool
(Affymetrix) [30].
RT-PCR
One µg of RNA was converted to cDNA (Reverse Tran-
scription system, Promega, Madison, WI) as described by
the manufacturer. cDNA from 100 ng of total RNA was
amplified with AmpliTaq DNA polymerase (Perkin Elmer,
Boston, MA), PCR products were separated by agarose gel
electrophoresis, normalized to GAPDH and quantified
using alpha imager spot densitometry (Alpha Innotech,
San Leandro, CA). DNA contamination was tested by per-
forming a control with no reverse transcriptase. The PCR
primers for p30II were as follows: TAG CAA ACC GTC AAG
CAC AG (forward) and CGA ACA TAG TCC CCC AGA GA
(reverse). The PCR primers for CHP were as follows: CCC
ACA GTC AAA TCA CTC GCC (forward) and ATG GTC
CTG TCT GCG ATG CTG (reverse). The PCR primers for
JUN-D were as follows: CTC TCA GTG CTT CTT ACT ATT
AAG CAG (forward) and TTA TCT AGG AAT TGT CAA
AGA GAA GATT (reverse). The PCR primers for NFATc
were as follows: TTG GGA GAG ACA TGT CCC AGA TT
(forward) and TCA TTT CCC CAA AGC TCA AAC A
(reverse). The results were expressed as a graph. Statistical
analysis was performed using Student's t test, P < 0.05.
Transient transfection and reporter gene assay
Analysis of AP-1, NF-κB, and NFAT transcriptional activity
in pME- and pME-p30II-transfected Jurkat T lymphocytes
was performed as described previously [50]. Briefly, tran-
sient transfection of Jurkat T lymphocytes was done by
electroporating 107 cells in cRPMI (RPMI 1640 containing
10% fetal bovine serum (FBS) and 10% streptomycin and
penicillin) at 350 V and 975 µF using Bio-Rad Gene Pulser
II (Bio-Rad, Laboratories, Hercules, CA) with 30 µg of
pME-p30 or pME empty plasmid, 10 µg of reporter plas-
mid (NFAT-Luc, AP-1 Luc or NF-κB Luc), and 1 µg of
pRSV-Gal plasmid or 1 ug pWPT-IRES-GFP plasmid. The
transfected cells were seeded in six-well plates at a density
of 5 × 105/ml and were either left untreated or stimulated
with 20 ng/ml of phorbol myristate acetate (PMA)
(Sigma) or with 2 µM ionomycin (Sigma), or both at 6 h
post-transfection, followed by incubation for 18 h prior to
lysis for analysis of luciferase activity. Stimulations with
anti-CD3 and/or anti-CD28 antibodies (each at 3 µg/ml)
(BD Pharmingen, San Diego, CA) were carried out 18 h
post-transfection. Following 8 h of stimulation, to meas-
ure luciferase activity, the cells were lysed with Cell Cul-
ture Lysis Reagent (Promega), and the cell lysates were
tested for luciferase activity according to the manufac-
turer's protocol. Transfection efficiency was normalized
by staining with 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside (X-Gal) (Sigma) and counting β-Gal
expressing cells. Transfection efficiency was also normal-
ized by counting GFP positive cells under the fluorescence
microscope. Results were expressed as mean of optimized
luciferase activity (luciferase activity/percentage cells
stained positive for β-Gal expression) in arbitrary light
units (ALU) with standard error (SE) from a minimum of
triplicate experiments. Statistical analysis was performed
using Student's t test, P < 0.05.
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